Neothetics (NEOT) Reports Q1 Loss of $0.44/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Neothetics Reports First Quarter 2016 Financial Results
May 12, 2016 8:03 AM EDTSAN DIEGO, May 12, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ: NEOT) today reported financial results and business progress for the first quarter 2016.
First Quarter 2016 Highlights
Neothetics plans to conduct a Phase 2 trial with a modified formulation of LIPO-202 in the third quarter of 2016 for the reduction of central abdominal bulging, which the company anticipates having top-line data from in the first quarter of 2017. This Phase 2 study will be a randomized, double-blind, placebo-controlled trial designed to assess the efficacy, safety and tolerability of a modified... More